ArticleJournal of radiosurgery and SBRT2013
Stereotactic radiosurgery for WHO II and III meningiomas: analysis of long-term clinical and radiographic outcomes.
Article in Journal of radiosurgery and SBRT, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Adult intraventricular meningiomas in contemporary neurosurgical practice: a systematic review and meta-analysis.Neurosurgical review · 2026Pooled it
- Frameless linac-based radiosurgery for benign intracranial tumors treated with HyperArc: analysis of tumor control and toxicity.Journal of neuro-oncology · 2025Article
- The Rationale for Early Adjuvant Radiotherapy After Gross Total Resection of Atypical Meningioma.Neurosurgery · 2025Article
- Radiosurgery in Grade II and III Meningiomas: A Systematic Review and Meta-Analysis.Journal of personalized medicine · 2024Review
- Customised pre-operative cranioplasty to achieve maximal surgical resection of tumours with osseous involvement-a case series.Acta neurochirurgica · 2024Article
- Adjuvant proton beam therapy in patients with grade 2 meningiomas.Surgical neurology international · 2024Article
- Radiotherapy and radiosurgery for meningiomas.Neuro-oncology advances · 2023Article
- Mapping angiography and transarterial technetium macroaggregated albumin particle simulation of recurrent atypical intracranial meningioma: feasibility for potential vascular brachytherapy.Radiology case reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimWHO grade II and III meningiomas are challenging tumors to treat, and the role of stereotactic radiosurgery (SRS) in their treatment is not well defined. We evaluate our experience to better define its role and assess for clinical and radiographic predictors of failure.
methodsThis is a retrospective analysis of all patients with histological diagnosis of WHO II or III meningioma. Thirteen patients were included. The mean dose to the periphery was 16 Gy (12-20), the mean maximum dose was 31 Gy (13-40), and the mean isodose line was 49% (35-50).
resultsThe median age was 48 years. The median follow up was 50 months (7-67). All cases had undergone at least one previous resection, and six patients had undergone external beam radiation (EBRT). The median pre SRS Karnofsky performance score (KPS) was 90. The progression free survival (PFS) was 92% and 31% at 1 and 4 years, respectively. Eleven patients required further treatment after SRS. The final tumor volume was decreased in 7 patients, stable in 1, and increased in 6.
conclusionsWHO grade II and III meningiomas are aggressive tumors that will require multiple treatments. SRS may be a useful as an adjuvant treatment or for recurrence.
Indexed as
Identifiers
29296361PMC5658810W2983285786What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.